Skip to main content

Advertisement

Table 3 s-RNY1-5p level according to high sensitive C-reactive protein (hs-CRP) levels, apolipoprotein B (ApoB) levels, statin therapy, and fibrate therapy and case–control (CC) status

From: RNY-derived small RNAs as a signature of coronary artery disease

CRP (mg/L) CC (s-RNY1-5p)1/7 CC effect hs-CRP effect CC × hs-CRP interaction
 <6 Case (n = 121) 1.30 (0.17) 0.001 0.03 0.72
 ≥6 Case (n = 142) 1.34 (0.18)    
 <6 Control (n = 449) 0.95 (0.18)    
 ≥6 Control (n = 65) 0.98 (0.20)    
ApoB (g/L) CC (s-RNY1-5p)1/7 CC effect ApoB effect CC × ApoB interaction
 <1.02 Case (n = 115) 1.30 (0.18) 0.001 0.001 0.79
 ≥1.02 Case (n = 148) 1.35 (0.17)    
 <1.02 Control (n = 200) 0.92 (0.19)    
 ≥1.02 Control (n = 314) 0.97 (0.19)    
Statin therapy CC (s-RNY1-5p)1/7 CC effect statin effect CC × statin interaction
 No Case (n = 115) 1.34 (0.18) 0.001 0.15 0.78
 Yes Case (n = 148) 1.31 (0.18)    
 No Control (n = 428) 0.95 (0.19)    
 Yes Control (n = 86) 0.93 (0.20)    
Fibrate therapy CC (s-RNY1-5p)1/7 CC effect fibrate effect CC × fibrate interaction
 No Case (n = 242) 1.33 (0.17) 0.001 0.21 0.46
 Yes Case (n = 21) 1.28 (0.19)    
 No Control (n = 472) 0.95 (0.19)    
 Yes Control (n = 42) 0.94 (0.18)